Healthcare

Highlights

  • Actinogen Medical (ASX:ACW) received a third independent safety review clearance for its XanaMIA Alzheimer’s trial.
  • The Phase 2b/3 study remains on track for topline efficacy results expected in November 2026.
  • Xanamem is being developed as an oral treatment targeting cortisol production in the brain.
  • The upcoming clinical readout remains the key milestone for the company’s future direction.

Actinogen Medical (ASX:ACW) has progressed another milestone in its XanaMIA Alzheimer’s trial, with the independent Data Monitoring Committee recommending that the study continue without changes following its latest safety review.

The update keeps the company on track towards its expected November 2026 topline efficacy results. For Actinogen, the outcome of this trial remains the central Factor determining the future development pathway for Xanamem, its lead therapeutic candidate.

What Happened?

On 18 June 2026, Actinogen announced that the independent committee overseeing the XanaMIA trial had completed a scheduled review of unblinded safety data and recommended that the study continue unchanged.

The committee’s assessment focused on safety and tolerability rather than efficacy.

This represented the third positive safety review for the trial. Earlier in January 2026, the same committee completed a prespecified interim analysis that included an efficacy-related futility assessment and recommended continuation of the study.

The reviews indicate that no safety concerns or trial-related issues have required changes to the study design.

Why It Matters

Actinogen Medical’s primary asset is Xanamem (emestedastat), an oral inhibitor targeting the enzyme 11β-HSD1.

The treatment is designed to reduce cortisol production within brain regions associated with memory and cognitive function, including the hippocampus and frontal cortex.

The approach differs from therapies targeting amyloid plaques, as Xanamem aims to influence a biological pathway linked to neuronal stress.

If successful, the treatment could provide a different therapeutic approach in Alzheimer’s disease, where current treatments remain limited by administration requirements and monitoring needs.

The Numbers

XanaMIA is a Phase 2b/3 pivotal trial evaluating Xanamem in patients with mild-to-moderate Alzheimer’s disease.

The study is double-blind, placebo-controlled and parallel-group in design, enrolling 247 participants across trial sites in Australia and the United States.

Participants receive either Xanamem 10 mg or placebo once daily over a 36-week treatment period.

Patient selection includes confirmation of Alzheimer’s pathology through elevated pTau181 blood biomarkers.

The primary endpoint is the change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB), which measures both cognitive performance and daily functioning.

At the time of the June review, more than 100 patients had completed the full treatment period.

Xanamem has previously been studied across eight Clinical Trials involving more than 500 volunteers and patients.

The Bigger Picture

The upcoming XanaMIA results need to be viewed alongside Actinogen’s previous clinical experience.

In the earlier XanaCIDD Phase 2a study evaluating cognitive Impairment associated with depression, Xanamem showed an improvement in depressive symptoms but did not meet its primary cognitive endpoint related to attention.

XanaMIA was designed with additional considerations, including biomarker-confirmed Alzheimer’s patients, a longer treatment period and a function-based primary endpoint.

Actinogen has also commenced an open-label extension study, XanaMIA-OLE, providing longer-term safety information from participants receiving Xanamem.

The recent safety reviews confirm continuation of the trial but do not demonstrate treatment effectiveness. The efficacy outcome remains dependent on the November 2026 data release.

The Bull Case

The positive case for Actinogen Medical (ASX:ACW) is based on the potential clinical differentiation of Xanamem and progress towards a major efficacy milestone.

The company has completed multiple safety reviews without changes to the XanaMIA trial, reducing uncertainty around trial continuation.

The use of biomarker-confirmed Alzheimer’s patients and a function-focused primary endpoint may provide clearer evidence of potential treatment effects.

A successful clinical outcome could support further development opportunities, including potential partnerships or additional regulatory pathways.

Risks Investors Should Understand

Actinogen Medical (ASX:ACW)’s Business faces risks including clinical trial failure, regulatory uncertainty, funding requirements and limited validation of its therapeutic approach.

The November 2026 XanaMIA readout represents a major binary event, as a negative or unclear result could significantly affect the company’s development pathway and future financing options.

The cortisol-modulation approach remains less established than other Alzheimer’s treatment mechanisms.

Even a positive result would require additional development, regulatory review and potential commercialisation steps before any treatment becomes available.

As a pre-revenue biotechnology company, Actinogen remains dependent on funding and milestone progress.

What Comes Next?

The key upcoming milestone is the expected November 2026 topline XanaMIA efficacy readout.

Investors will focus on whether Xanamem demonstrates a statistically significant difference versus placebo on the CDR-SB primary endpoint.

Additional areas of attention will include secondary cognitive measures, biomarker changes, safety outcomes and potential regulatory discussions.

The company’s ability to attract development partners and progress future clinical programs will likely depend heavily on the trial outcome.

Conclusion

Actinogen Medical (ASX:ACW) has cleared another safety milestone for its XanaMIA Alzheimer’s trial, keeping the study on track towards its expected efficacy readout.

The latest review reduces procedural uncertainty but does not provide evidence that Xanamem is effective in slowing cognitive decline.

The November 2026 results will represent the defining milestone for the company, determining whether its cortisol-modulation approach can translate into meaningful clinical outcomes.